With PhII fail, Redx Phar­ma scraps monother­a­py bil­iary can­cer de­vel­op­ment for lead pro­gram

UK biotech Redx Phar­ma’s lead drug has failed a Phase II study for bil­iary tract can­cer, and the re­sults are “not suf­fi­cient” to con­tin­ue de­vel­op­ment as a monother­a­py in that in­di­ca­tion, the com­pa­ny an­nounced Wednes­day.

RXC004, a por­cu­pine in­hibitor be­ing de­vel­oped to treat Wnt-lig­and de­pen­dent can­cers in pa­tients whose dis­ease pro­gressed af­ter oth­er treat­ments, failed to hit the pri­ma­ry end­point — pro­gres­sion-free sur­vival at six months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER